The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single-ascending dose study and a 14-day multiple-ascending dose (MAD) monotherapy study. However, HCV RNA remained detectable in genotype 1a-infected patients at the end of the MAD study. In contrast, viral breakthrough was observed less often in patients infected with genotype 1b, and, in several patients, HCV RNA declined and remained below the level of quantitation (<25 IU/mL) through the duration of treatment. Here, we report on the results of the genotypic and phenotypic analyses of resistant variants in 24 genotype 1-infected patients who received BMS-790052 (1, 10, 30, 60, and 100 mg, once-daily or 30 mg twice-daily) in the 14-day MAD study. Sequence analysis was performed on viral complementary DNA isolated from serum specimens collected at baseline and days 1 (4, 8, and 12 hours), 2, 4, 7, and 14 postdosing. Analyses of the sequence variants (1) established a correlation between resistant variants emerging in vivo with BMS-790052 treatment and those observed in the in vitro replicon system (major substitutions at residues 28, 30, 31, and 93 for genotype 1a and residues 31 and 93 for genotype 1b); (2) determined the prevalence of variants at baseline and the emergence of resistance at different times during dosing; and (3) revealed the resistance profile and replicative ability (i.e., fitness) of the variants. Conclusion: Although resistance emerged during monotherapy with BMS-790052, the substantial anti-HCV effect of this compound makes it an excellent candidate for effective combination therapy. (HEPATOLOGY 2011;54:1924-1935 T he hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a multifunctional protein with key roles in HCV replication. NS5A has also been implicated in the modulation of cellular signaling pathways. 1,2 Because it is required in vivo and in vitro for viral replication and has no known human homologs, NS5A provides an attractive target for therapeutic intervention. 3 BMS-790052 is a potent HCV NS5A replication complex inhibitor, with 50% effective concentration (EC 50 ) values of 9 and 50 pM against genotype 1b and 1a replicons, respectively. 4,5 It is also potent against live virus (genotype 2a, JFH-1), with an EC 50 of $28 pM. 4 BMS-790052 has broad genotype coverage, with EC 50 values ranging from pM to low nM for replicons with NS5A sequences derived from genotype 2a, 3a, 4a, and 5a. 4
With the fast development of organic electronics, organic semiconductors have been extensively studied for various optoelectronic applications, among which organic phototransistors recently emerged as one of the most promising light signal detectors. However, it is still a big challenge to endow organic phototransistors with both high mobility and high light-sensitivity because the low mobility of most organic photoresponsive materials limits the efficiency of transporting and collecting charge carriers. We herein report band-like charge transport in vacuum-deposited small-molecule thin films for organic phototransistor arrays which can be operated at very low dark currents (~10−12 A). Both high mobility and excellent optical figures of merit including photosensitivity, photoresponsivity and detectivity are achieved, wherein, unprecedentedly, a detectivity greater than 1017 cm Hz1/2 W−1 is obtained. All these key parameters are superior to state-of-the-art organic phototransistors, implying a great potential in optoelectronic applications.
Recent advances in photoswitchable molecular devices based on single molecules or self-assembled monolayers of photochromic molecules are summarized and discussed.
Phototransistors combine light detection and signal amplification functions into a single device and are regarded as one of the most important components for optoelectronic integration. In recent years, organic phototransistors (OPTs) have attracted worldwide interest because of their potential advantages of low cost, light weight, excellent flexibility and broadband detection. In this review, a brief description of the working mechanisms and performance metrics of OPTs is presented. Afterwards, the recent progress of OPTs based on the conventional planar fieldeffect transistor structure is presented. Furthermore, from the perspective of novel device architectures and interface engineering, strategies for improving the performance of OPTs are discussed. Flexible optoelectronic devices based on OPTs for potential application in next-generation wearable and humanfriendly electronics are also highlighted. Finally, an outlook for future research directions and challenges for OPTs is provided.
BMS-790052, a first-in-class hepatitis C virus (HCV) replication complex inhibitor, targeting nonstructural protein 5A (NS5A), displays picomolar to nanomolar potency against genotypes 1 to 5. This exceptional potency translated into robust anti-HCV activity in clinical studies with HCV genotype 1-infected subjects. To date, all BMS-790052-associated resistance mutations have mapped to the N-terminal region of NS5A. To further characterize the antiviral activity of BMS-790052, HCV replicon elimination and colony formation assays were performed. Replicon was cleared from genotype 1a and 1b replicon cells in a time-and dose-dependent manner. Elimination of the genotype 1a replicon required longer treatment durations and higher concentrations of BMS-790052 than those for the genotype1b replicon. Single amino acid substitutions that conferred relatively low levels of resistance were observed at early time points and at low doses. Higher doses and longer treatment durations yielded mutations that conferred greater levels of resistance, including linked amino acid substitutions. Replicon cells that survived inhibitor treatment remained fully sensitivity to pegylated alpha interferon (pegIFN-␣) and other HCV inhibitors. Moreover, genotype 1a replicon elimination was markedly enhanced when pegIFN-␣ and BMS-790052 were combined. Resistant variants observed in this study were very similar to those observed in a multiple ascending dose (MAD) monotherapy trial of BMS-790052, validating replicon elimination studies as a model to predict clinical resistance. Insights gained from the in vitro anti-HCV activity and resistance profiles of BMS-790052 will be used to help guide the clinical development of this novel HCV inhibitor. H epatitis C virus (HCV), a member of the Flaviviridae family of RNA viruses, is a major cause of liver disease worldwide (1). The ϳ9.6-kb HCV genome encodes a polyprotein that is processed into structural proteins (core, E1, and E2), a small ion channel protein (p7), and nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) required for polyprotein processing and RNA replication (2). Until very recently, standard-of-care therapy for HCV-infected individuals consisted of a combination of pegylated interferon (pegIFN) and ribavirin (RBV) (18). Because of complications with side effects and incomplete antiviral efficacy, only ϳ50% of individuals infected with HCV genotype 1 achieved a sustained viral response upon treatment (18). Today, an increasing number of small-molecule inhibitors targeting specific viral proteins are in various stages of development, and two drugs that target the HCV NS3 protease, telaprevir and boceprevir, have been approved for clinical use for HCV genotype 1-infected patient treatment in combination with pegIFN and RBV. Collectively referred to as directly acting antiviral agents (DAA), these virus-specific inhibitors hold the promise of improving or even replacing IFN-based HCV therapy (9). Many of the DAA in development are directed against the viral enzymatic activities...
A comparison of the daclatasvir (DCV [BMS-790052]) resistance barrier on authentic or hybrid replicons containing NS5A from hepatitis C virus (HCV) genotypes 1 to 6 (GT-1 to -6) was completed using a replicon elimination assay. The data indicated that genotype 1b (GT-1b) has the highest relative resistance barrier and genotype 2a (GT-2a M31) has the lowest. The rank order of resistance barriers to DCV was 1b > 4a > 5a > 6a Х 1a > 2a JFH > 3a > 2a M31. Importantly, DCV in combination with a protease inhibitor (PI) eliminated GT-2a M31 replicon RNA at a clinically relevant concentration. Previously, we reported the antiviral activity and resistance profiles of DCV on HCV genotypes 1 to 4 evaluated in the replicon system. Here, we report the antiviral activity and resistance profiles of DCV against hybrid replicons with NS5A sequences derived from HCV GT-5a and GT-6a clinical isolates. DCV was effective against both GT-5a and -6a hybrid replicon cell lines (50% effective concentrations [EC 50 s] ranging from 3 to 7 pM for GT-5a, and 74 pM for GT-6a). Resistance selection identified amino acid substitutions in the N-terminal domain of NS5A. For GT-5a, L31F and L31V, alone or in combination with K56R, were the major resistance variants (EC 50 s ranging from 2 to 40 nM). In GT-6a, Q24H, L31M, P32L/S, and T58A/S were identified as resistance variants (EC 50 s ranging from 2 to 250 nM). The in vitro data suggest that DCV has the potential to be an effective agent for HCV genotypes 1 to 6 when used in combination therapy. D aclatasvir (DCV [BMS-790052]) is a cross-genotypic NS5Ainhibitor with picomolar to low nanomolar potency in the replicon system (1, 2). The antiviral activity of DCV in vitro translated into clinical efficacy, with hepatitis C virus (HCV) RNA declines of ϳ3 to 4 log 10 observed in genotype 1a (GT-1a)-infected subjects treated once daily (QD) with 60 mg of DCV in a 14-day multiple ascending dose (MAD) monotherapy study (3, 4). Moreover, DCV was effective against GT-1b and -1a in combinations that include either pegylated interferon and ribavirin (PEG-IFN-RBV) or other direct-acting anti-HCV agents (DAAs) (5-8).There are large populations of viral quasispecies preexisting in infected individuals, and variants that confer resistance to antiviral agents can be rapidly enriched and/or selected during antiviral treatment (9-11). Since DCV resistance variants show no crossresistance to other DAAs, DCV should rapidly suppress wild-type virus and variants resistant to other DAAs, thereby enhancing the effectiveness of other DAAs in combination therapies (2, 3). This effect is predicted to lead to higher rates of sustained viral response (SVR) and/or shorten the duration of treatment necessary to achieve SVR. Recent clinical results with DCV plus asunaprevir (ASV ) in patients infected with GT-1b and with DCV plus sofosbuvir (SOF ) in patients infected with GT-1, -2, and 3 demonstrate the effectiveness of DCV in interferon-free DAA combination therapies (6,12).Prior studies using the in vitro replicon system in...
Photochemical crystal ↔ liquid transitions (PCLTs) are interesting phenomena that couple reversible photochemical transformations with thermophysical phase transitions. A potential application of PCLTs is the development of photoresponsive smart materials capable of exerting reversible adhesion capacities on specific surfaces at a desired timing, which are unattainable for conventional adhesives. However, PCLT-based adhesives generally use UV light as the stimulus, which could lead to degradation of materials and health problems. Here, visible-light-controlled smart and robust adhesives are developed using small-molecule azo photoswitches. These azo molecules can undergo very efficient trans-crystal → cis-liquid and cis-liquid → trans-crystal transitions under 405 and 532 nm light irradiations, respectively. Their trans-crystal state displays strong adhesion strengths on various substrates, e.g., 1.13 MPa on quartz/quartz and 1.58 MPa on wood/wood, and very fast light-induced separation of glued substrates can be accomplished within 1 s along with the loss of adhesion strength in the cis-liquid state. Robust switching of the adhesion strength is demonstrated in multiple cycles, and these adhesives can also work well in underwater environments. Visible-light-controlled reversible PCLTs can be a very promising strategy in the pursuit of high-performance photoresponsive adhesives.
The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC 50 s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.